The GSSP for the base of the Eocene Series is located at 1.58 m above the base of Section DBH in the Dababiya Quarry, on the east bank of the Nile River, about 35 km south of Luxor, Egypt. It is the base of Bed 1 of t...
详细信息
The GSSP for the base of the Eocene Series is located at 1.58 m above the base of Section DBH in the Dababiya Quarry, on the east bank of the Nile River, about 35 km south of Luxor, Egypt. It is the base of Bed 1 of the Dababyia Quarry Beds of the El Mahmiya Member of the Esna Formation, interpreted as having recorded the basal inflection of the carbon isotope excursion (CIE), a prominent (3 to 5%) geochemical signature which is recorded in marine (deep and shallow) and terrestrial settings around the world. The Paleocene/Eocene boundary is thus truly a globally correlatable chronostratigraphic level.
Purpose: Although controversial, assessment of epidermal growth factor receptor (EGFR) expression is required for the approved indications of Cetuximab in metastatic colorectal cancer (mCRC). With the objective of imp...
详细信息
Purpose: Although controversial, assessment of epidermal growth factor receptor (EGFR) expression is required for the approved indications of Cetuximab in metastatic colorectal cancer (mCRC). With the objective of improving patient selection, “ERBITUX-OUEST” study aimed at analyzing EGFR status in a large cohort of mCRC patients who received cetuximab without preliminary EGFR screening, and assessing the correlation between EGFR status and response to treatment retrospectively. Patients and methods: 332 patients treated with Irinotecan Cetuximab based regimen after progression on irinotecan or oxaliplatin therapy were included. EGFR status was assessed using three available immunohistochemistry (IHC) tests and in situ hybridization in case of negativity. Clinical outcomes of EGFR-positive and EGFR-non-detected (or considered as negative with at least one test) patients were compared. Results: Of the 332 samples centrally screened, 194 were classified as full-positive (i.e., EGFR-positive for all three tests), 86 as full-negative, and 52 as discordant. One third of the 131 negative samples with FDA approved test should be reclassified as positive with at least one of the two others tests. Regarding results from FDA approved test only, neither objective response rate (ORR), progression-free survival (PFS) nor overall survival (OS) differed significantly between EGFR-negative and EGFR-positive patients (P = 0.788, 0.326 and 0.888, respectively). Similarly, comparison of full-negative to other groups did not show any significant difference in terms of ORR (P = 0.507), PFS (P = 0.222) or OS (P = 0.686). Conclusion: These data strongly argue against mCRC patients selection for Cetuximab treatment based on EGFR expression as measured by currently available IHC technics.
暂无评论